

- **Investment Rational**

Trobix-Bio empowers engineered phages with CRISPR to modify microbiome traits, developing a pipeline of microbiome-based therapeutics addressing unmet medical needs such as antimicrobial-resistance, oncology, and gut inflammation. The company's products address multi-billion-dollar market opportunities. TBX101 is advancing lead development while TBX201 has positive PoC findings. The company is led by a highly experienced team and backed by international KOLs.

- **Business Strategy**

Trobix-Bio business model is to sign on license agreements for its innovative drugs to pharma companies. Trobix-Bio and Pharma company will co-develop the technology for the licensed indication. The pharma company will be responsible for product commercialization. Trobix-Bio will enjoy short term revenues in the form of upfront and milestone payments and longer-term revenue payments as royalties on products sales.

- **Core Technology**

The TBX platform combines proprietary molecular phage engineering and computational tools for the precision delivery of DNA payloads. Our platform is the only technology capable of modifying bacterial traits by in-vivo selecting the desired bacterial population. Exerting a lasting and continuous effect enables us to remove unwanted traits, control activity of specific bacteria, and introduce biotherapeutics to our gut microbiome.

- **Product Profile/Pipeline**

With a \$3B addressable market, TBX101, at an advanced lead product development stage, targets high risk hospitalized patients that carry a gut superbug. TBX201, with positive in-vitro PoC findings and a \$1.8B market potential, offers to reduce side effects caused by a widely used cancer drug. TBX301 offers a potentially game-change solution to gut inflammation, holding a \$6B market potential.

- **What's Next?**

The company plans to raise a significant funding round, which proceeds will be used to reach value enhancing KPI's: Initiating First-in-Man clinical trial for its lead product, TBX101; Advancing non-clinical development of TBX201 and TBX301; Creating strong infrastructure capabilities for rapid development of new pipeline products and GMP manufacturing of the company's products; Generating collaborations with Pharma companies.